Systemic anti-inflammatory mediators in COPD: Increase in soluble interleukin 1 receptor II during treatment of exacerbations

Thorax

Volumn 56, Issue 9, 2001, Pages 721-726

  Dentener, M A ^a   Creutzberg, E C ^a   Schols, A M W J ^a   Mantovani, A ^b   Van't Veer, C ^a   Buurman, W A ^a   Wouters, E F M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Soluble interleukin 1 receptor II; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR; IPRATROPIUM BROMIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; PREDNISOLONE; PROTEIN P55; RECEPTOR SUBTYPE; SALBUTAMOL; THEOPHYLLINE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARRIER PROTEINS; CHRONIC DISEASE; CYCLIC AMP RECEPTOR PROTEIN; DNA-BINDING PROTEINS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VITAL CAPACITY;

EID: 0034853377     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.56.9.721     Document Type: Article

References (34)

1. Medical progress: Chronic obstructive pulmonary disease
2. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
3. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease
4. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease
5. Airway eosinophilia in chronic bronchitis during exacerbations
6. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ)
7. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations
8. Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction
9. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels
10. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease
11. Role of pro- and anti-inflammatory cytokines during inflammation: Experimental and clinical findings
12. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4
13. Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids
14. Multi functional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors
15. TNF receptors: How they function and interact
16. BTS guidelines for the management of chronic obstructive pulmonary disease
17. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society
18. A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise
19. Slow release of soluble TNF receptors by monocytes in vitro
20. Lipopolysaccharide toxicity-regulating proteins in bacteremia
21. Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes
22. Statistical guidelines for contributors to medical journals
23. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease
24. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia
25. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses
26. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD
27. Factors influencing airway inflammation in chronic obstructive pulmonary disease
28. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes
29. Airways inflammation in chronic bronchitis: The effects of smoking and alpha-1-antitrypsin deficiency
30. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis
31. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease
32. Role of metalloproteases in the release of the IL- type II decoy receptor
33. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types
34. Extracellular regulation of interleukin (IL)-1 beta through lung epithelial cells and defective IL-1 type II receptor expression